The price-to-earnings ratio for Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is 212.44x, which is above its average ratio. Moreover, the 36-month beta value for AUPH is
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has a price-to-earnings ratio of 209.84x that is above its average ratio. Additionally, the 36-month beta value for AUPH is
The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has plunged by -3.81 when compared to previous closing price of 7.20, but the company has
The stock of Aurinia Pharmaceuticals Inc (AUPH) has seen a -3.87% decrease in the past week, with a 1.36% gain in the past month, and
The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has dropped by -1.73 compared to previous close of 8.67. Despite this, the company has seen
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has a price-to-earnings ratio of 218.52x that is above its average ratio. Additionally, the 36-month beta value for AUPH is
© 2024, Powered by Smart TechOne
